Oramed Pharmaceuticals Inc.
ORMP
$2.33
$0.031.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -444.98% | 127.30% | 203.32% | 135.41% | 115.11% |
| Total Depreciation and Amortization | -1.53% | 34.38% | 79.34% | 155.95% | 237.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 154.47% | -602.52% | -636.33% | -402.76% | -239.80% |
| Change in Net Operating Assets | 218.69% | 172.00% | 192.12% | -809.92% | -185.90% |
| Cash from Operations | 18.29% | 53.25% | 91.82% | 74.44% | 63.12% |
| Capital Expenditure | 92.91% | 98.21% | 94.29% | 91.20% | 48.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 245.41% | 231.96% | 637.60% | -389.89% | -337.21% |
| Cash from Investing | 244.88% | 231.18% | 615.61% | -409.22% | -341.76% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | 0.90% | -198.20% | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -100.00% | -100.00% | -78.98% |
| Repurchase of Common Stock | -124,200.00% | -64,450.00% | 98.11% | 98.13% | 99.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -200.11% | -193.45% | -100.02% | 179.82% | 382.22% |
| Foreign Exchange rate Adjustments | 92.59% | 103.59% | 78.95% | 80.46% | 15.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 244.43% | 232.13% | 437.24% | -43.10% | -341.46% |